First author (year) | Total patients/patients aged ≥70 years n | Treatment arms | Response rate <70 years/≥70 years % | Median survival time <70 years/≥70 years months | 1-year survival rate <70 years/≥70 years % |
Langer (2002) | 574/86 | CDDP + VP16 versus CDDP + Pacli | 21.5/23.3# | 9.1#/8.5 | 38#/29 |
Lilenbaum (2005) | 561/155 | Carbo + pacli versus pacli | 28#/36 15/21 | 9#/8 6.8/5.8 | 38#/33 35/31 |
Belani (2005) | 1218/401¶ | CDDP + Doc versus Carbo + Doc versus CDDP + VNR | 11.0/12.6 9.7/9 10.1/9.9 | 44/52 37/39 41/41 | |
Ansari (2011) | 1135/338 | Carbo + Gem Pacli + Gem Carbo + Pacli | 30.1/28.2 24.8/24.4+ | 7.7/8.8/8.0/7.2 8.9/9.8/5.9/7.8 9.4/8.4/6.1/7.9§ | |
Blanchard (2011) | 616/122 | CDDP + VNR versus Carbo + Pacli | 27/30 | 9/7 (p = 0.04) | 40/27 |
CDDP: cisplatin; VP16: etoposide; Carbo: carboplatin; Pacli: paclitaxel; Doc: docetaxel; VNR: vinorelbine; Gem: gemcitabine. #: global percent or median survival time for the two arms together; ¶: 401 patients aged ≥65 years; +: Response rate by categories of age, the three arms being combined: <70 years, 70–74 years, 75–79 years, ≥80 years; §: median survival by arm and age categories; no significant difference.